AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Artificial Intelligence Assistance of Pancreatic Exocrine Insufficiency Evaluation in Chronic Pancreatitis From Contrast-Enhanced CT
1 other identifier
observational
504
1 country
1
Brief Summary
Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients. A total of 504 patients with CP who underwent fecal elastase-1 test and contrast-enhanced CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. The investigators aim to establish a fully automated workflow to establish a PEI classification model based on radiomic features, semantic features and deep learning features on enhanced CT images for evaluating the severity of PEI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
January 22, 2024
CompletedFirst Posted
Study publicly available on registry
February 26, 2024
CompletedFebruary 26, 2024
January 1, 2024
10 months
January 22, 2024
February 22, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Classification of pancreatic exocrine insufficiency
Pancreatic exocrine insufficiency are classified by FE-1 test into severe (0-100), mild to moderate (100-200) and normal (\>200).
Up to 10 months
Eligibility Criteria
A total of 504 patients with CP who underwent the FE-1 test and CE-CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. the exclusion criteria were as follows: (a) enhanced CT was taken during the acute episode of chronic pancreatitis, (b) history of malignant tumor, (c) previous pancreatic surgery, (4) systemic diseases, and (5) poor image quality or image loss
You may qualify if:
- gender and age are not restricted
- diagnosis of chronic pancreatitis
- fe-1 test was conducted following recent pancreatic enhanced CT
- sign informed consent
You may not qualify if:
- enhanced CT was taken during the acute episode of chronic pancreatitis
- history of malignant tumor
- previous pancreatic surgery
- systemic diseases
- poor image quality or image loss
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Changhai Hospital
Shanghai, 200433, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 22, 2024
First Posted
February 26, 2024
Study Start
March 1, 2023
Primary Completion
January 1, 2024
Study Completion
January 1, 2024
Last Updated
February 26, 2024
Record last verified: 2024-01